Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | MMP3 | P08254 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP7 | P09237 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156567 | 0.85 | SLC1A3 (0.34) | SLC1A3SLC1A2SLC1A1MMP2MMP3 | |
| SCHEMBL1156468 | 0.84 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1MMP2MMP3 | |
| SCHEMBL1156881 | 0.81 | PTGDR2 (0.39) | MMP2MMP3MMP1MMP7MMP9 | |
| SCHEMBL1156908 | 0.80 | HTR6 (0.40) | PTGDR2PTGS2 | |
| SCHEMBL1156427 | 0.79 | KMT2A (0.37) | SLC1A3SLC1A2SLC1A1PTGDR2IDH2 | |
| SCHEMBL1278067 | 0.79 | FPR1 (0.40) | PTGDR2PTGS2 | |
| SCHEMBL2416815 | 0.79 | GRM4 (0.33) | MMP2MMP9MMP13PTGDR2ADAMTS4 | |
| SCHEMBL2408353 | 0.78 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1763241 | 0.78 | PRMT6 (0.41) | SLC1A3SLC1A2SLC1A1IDH2PTGS2 | |
| SCHEMBL1156426 | 0.78 | KMT2A (0.40) | SLC1A3SLC1A2SLC1A1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | SLC1A3 1705/4885SLC1A2 1872/4885SLC1A1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.